Chemical | 11 May 2021
Vivimed Labs to manufacture, market Favipiravir tablets
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The ratings also factor in the healthy net worth and comfortable capital structure of the Group at a consolidated level
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
BASF India has posted net profit of Rs.552.61 crores for the 12 months period ended March 31, 2021
The company reported total income of Rs.1997.79 crores during the period ended March 31, 2020.
Brenntag confirms its operating EBITDA guidance for the full year to be in a range of 1.08 to 1.18 billion EUR
UPL will obtain exclusive rights to develop, register and commercialize formulations of Flupyrimin for foliar applications in rice in Southeast Asia
NFIL remains excited on new opportunities and plans for a new innovation centre outside India
Industrial exhaust gas used to produce sustainable alcohol
For the first time in its history, Sadara’s net profits after Zakat & Tax in this first quarter exceeded SAR 1.6 billion
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Industry might reduce production as well as import of Di-ammonium Phosphate and shift focus towards other grades of phosphatic fertilizers
Evonik is more positive about its earnings for the year as a whole after posting a strong first quarter
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
ULTRASIL 4000 GR is the first low surface area silica with very good dispersibility
Operating income is expected to increase in all segments excepting the others segment
ICICI Direct expects the pharma segment to grow at 15% CAGR in FY21-23E to Rs 1407 crore
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Subscribe to our newsletter & stay updated.
